NY-IFF
25.6.2020 14:02:08 CEST | Business Wire | Press release
Regulatory News:
IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, today published its 2019 Sustainability Report, “Do More Good.” The title references a pillar of the Company’s purpose, To redefine how we live in and care for the resources of our world , which was launched last year as part of its most significant rebrand in 40 years. The report highlights IFF’s sustainability accomplishments throughout the business and covers the Company’s achievements in leveraging sustainable practices within its global footprint.
Andreas Fibig, IFF Chairman and CEO, said: “The leadership position that we have taken in sustainability is a reflection of the passion to do more good that’s been embraced by our people everywhere at IFF. We credit our customers, partners and suppliers for the incredible and productive alliances we have forged together in the service of sustainability. This is not a journey we can – or want - to take alone. It requires the energy and commitment of like-minded allies willing to challenge the status quo – and each other – to do what is ultimately best for people and planet.”
The 2019 report highlights include:
- IFF’s new purpose and Vision 2021 strategy, reflecting the importance of sustainability as a way of doing business at IFF
- External recognitions for IFF’s sustainability leadership, such as Barron’s, FTSE4Good, RobecoSAM Industry Mover award, Euronext Vigeo, and CDP A list
- Continued commitment to climate action, as demonstrated by the opening of the Union Beach, New Jersey solar array, the signing of the U.N. Business Ambition for 1.5°C: Our Only Future pledge, and strong progress against its environmental goals for greenhouse gas emission reductions (including a decrease in absolute emissions of 5.7% from prior year), and zero waste to landfill and water stewardship
- Strengthening of IFF’s responsible sourcing program and natural ingredient supply chains through new certifications, as well as by accelerating industry-leading blockchain technology as a tool for ensuring ingredient traceability
- Achieving an industry breakthrough in circular design and transparency with Henry Rose, a line of fine fragrances founded by actress Michelle Pfeiffer and created to the strictest environmental standards as defined by the Environmental Working Group and the Cradle to Cradle Products Innovation Institute
- External recognitions and certifications for IFF’s diversity & inclusion leadership, such as DiversityInc., Human Rights Campaign, EDGE, and the signing of the U.N. Global LGBTI Standards of Conduct for Business and the U.N. Women’s Empowerment Principles
- Accelerated the inclusion of legacy Frutarom data, where available, in response to stakeholder interest and to prepare for the anticipated merger with DuPont’s Nutrition & Biosciences business. This process included a significant data collection and training effort for more than 60 facilities in 27 countries.
Dr. Greg Yep, IFF’s Chief Scientific & Sustainability Officer, said, “IFF’s sustainability accomplishments are considerable and meaningful and I must thank our global network of green teams who are empowered to drive change for IFF and our communities. As pleased as we are with our results, from external recognitions to meeting and exceeding our goals, I know I speak for all of IFF when I confirm our commitment to continually improve and drive better outcomes, and always seeks ways to live up to our purpose and do more good.”
To read IFF’s 2019 Sustainability Report, visit iff.com/sustain and use #SustainxIFF to follow the conversation on its social channels.
# # #
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005417/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
